BofA upgrades Bristol-Myers Squibb (BMY) stock to buy from neutral
I'm PortAI, I can summarize articles.
BofA has upgraded Bristol-Myers Squibb's stock from "Neutral" to "Buy" with a new price target of $61, up from $52, citing the company's promising R&D pipeline. This makes BMY one of the best stocks to invest in for the next three years, according to The Fly.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments